医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Courtagen Initiates Partnership with Sciencewerke for International Distribution of Clinical Next Generation Sequencing Tests for Neurological and Metabolic Disorders

2014年05月29日 PM08:02
このエントリーをはてなブックマークに追加


 

WOBURN, Mass.

Courtagen Life Sciences, Inc., an innovative molecular information company, announced today an international distribution agreement with Sciencewerke. Sciencewerke is headquartered in Singapore, and has offices in Malaysia and Indonesia. The company anticipates this partnership will serve as a model for similar commercial relationships with leading distributors in markets around the world.

Often diagnosis of pediatric neurological and metabolic disorders is challenging due to the wide range of symptoms and severity. Multiple lines of evidence support that genetic factors play a pivotal role. Courtagen’s genetic tests take advantage of recent advances in Next Generation Sequencing technology, and enable new opportunities to elucidate genetic causes of disorders such as epilepsy, intellectual disability, autism spectrum disorders, and mitochondrial dysfunction to guide treatment to improve the patient’s quality of life.

“We are excited to expand our molecular diagnostic offering to include Courtagen’s clinical testing for neurodevelopmental disorders, epilepsy, and mitochondrial disease,” said Dr. Vijay Bhandari, Business Development Director at Sciencewerke. “We look forward to quickly making these tests available to our medical facilities and clinicians throughout Singapore, Indonesia, and Malaysia.”

“The distribution agreement with Sciencewerke is an important part of global strategy to support the increasing demand of our products,” said Brendan McKernan, President of Courtagen. “We look forward to a successful partnership as we expand our global reach of genetic testing to clinicians and patients.”

About Courtagen Life Sciences, Inc.

Courtagen is a privately-held life sciences and molecular information company that converts genomic data into actionable clinical information for the diagnosis of critical pediatric neurological and metabolic disorders. Specifically, Courtagen focuses on mitochondrial disorders, epilepsy, and intellectual disability, including autism spectrum disorders. Courtagen’s state-of-the-art Next-Generation Sequencing clinical laboratory integrates genotype, phenotype, and disease mechanism data using cloud-based computing and custom analytical methods to provide the most comprehensive results for clinicians, patients, and their families to better understand and treat their disease. More information can be found at www.courtagen.com.

CONTACT

Courtagen Life Sciences, Inc.
Lori Emrick, 877-395-7608
lori.emrick@courtagen.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc